Your browser doesn't support javascript.
loading
The Use of Iloprost in the Treatment of Bone Marrow Edema Syndrome of the Proximal Femur: A Review and Meta-Analysis.
Zippelius, Timo; Strube, Patrick; Rohe, Sebastian; Schlattmann, Peter; Dobrindt, Oliver; Caffard, Thomas; Awan Malik, Hassan; Lindemann, Chris; Matziolis, Georg; Böhle, Sabrina.
Afiliação
  • Zippelius T; Department of Orthopedic Surgery, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
  • Strube P; Orthopedic Department, Jena University Hospital, Campus Eisenberg, 07607 Eisenberg, Germany.
  • Rohe S; Orthopedic Department, Jena University Hospital, Campus Eisenberg, 07607 Eisenberg, Germany.
  • Schlattmann P; Institute of Medical Statistics, Computer Sciences and Documentation, Jena University Hospital, 07743 Jena, Germany.
  • Dobrindt O; Department of Orthopedic Surgery, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
  • Caffard T; Department of Orthopedic Surgery, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
  • Awan Malik H; Department of Orthopedic Surgery, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
  • Lindemann C; Orthopedic Department, Jena University Hospital, Campus Eisenberg, 07607 Eisenberg, Germany.
  • Matziolis G; Orthopedic Department, Jena University Hospital, Campus Eisenberg, 07607 Eisenberg, Germany.
  • Böhle S; Orthopedic Department, Jena University Hospital, Campus Eisenberg, 07607 Eisenberg, Germany.
J Pers Med ; 12(11)2022 Oct 23.
Article em En | MEDLINE | ID: mdl-36573724
Objective: The aim of this meta-analysis was to investigate the impact of intravenous iloprost therapy on pain, function, edema changes, and follow-up surgery in bone marrow edema syndrome of the proximal femur. Methods: A systematic literature search up to May 2022 was performed to find relevant papers that made a statement about the outcome of intravenous iloprost therapy alone. Factors such as the Visual Analog Scale (VAS), Harris Hip Score (HHS), edema reduction, and follow-up interventions were considered. These were compared using Forest plots. Results: In 11 studies, 190 proximal femora with bone marrow edema syndrome that received intravenous iloprost therapy without further therapeutic intravenous or surgical intervention such as core decompression were studied. There was a significant mean improvement in VAS by 3.3 cm (2.07−4.5 cm) (p < 0.001) and HHS by 24.36 points (18.23−30.49) (p < 0.001) 3−6 months after receiving iloprost therapy. Only in 9.3% of cases (1.1−24.3%) did no clinical or radiological improvement occur. Conclusions: It could be shown that the existing publications support intravenous therapy with iloprost in patients with bone marrow edema syndrome and result in good clinical outcomes.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article